Skip to Main Content

Paper Details

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
NPJ Breast Cancer
25
2019
ER, ER+, ER+ breast cancer, ER+ breast cancer cell lines, HER2, MAP3K1, MAP3K1 mutations, NVP-BKM-120, PI3K, PIK3CA, Patients, alpelisib, alpha isoform, breast cancer, buparlisib, human, human epidermal growth factor-2, letrozole, luminal, luminal A subtype, luminal A tumors, metastatic breast cancer, patients, phosphoinositide 3-kinase, therein, tumors
Author NameAffiliation
Ingrid A MayerVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Ingrid A MayerVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Paula I Gonzalez-EricssonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Paula I Gonzalez-EricssonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Steven J IsakoffMassachusetts General Hospital
Melinda E SandersVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Melinda E SandersVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Michael F Berger6Memorial Sloan Kettering Cancer Center New York
Lewis C Cantley7Weill Cornell Medical College
Eric P Winer8Dana-Farber Cancer Institute
Justin M BalkoVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Justin M BalkoVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Justin M BalkoVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
  • 1 - 13

Datasets

Release 1.2